LONDON – Britain’s health chief says a new study showing that a single dose of the COVID-19 vaccine developed by Oxford University and AstraZeneca provides a high level of protection for 12 weeks supports the government’s strategy of delaying the second shot so more doses can be delivered to more people.
Health Secretary Matt Hancock's comments came after Oxford released a study showing the vaccine cut transmission of the virus by two-thirds and prevented severe disease.
The study has not been peer-reviewed yet, but it was greeted with excitement by U.K. officials under pressure to justify their decision to delay the second dose. “That reduction in transmission, as well as the fact there is no hospitalizations, the combination of that is